Wednesday, October 28, 2026Eastern Time · Updated through the dayRSS

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

Is Novo Nordisk (CPSE:NOVO B) Still Reasonable After New Semaglutide Data?

MH

By Maren Holt · Senior Reporter, GLP-1

Oct 7 03:00 ETSource: Yahoo Finance

From the source

Is Novo Nordisk (CPSE:NOVO B) Still Reasonable After New Semaglutide Data?

Read at finance.yahoo.com

Source URL https://finance.yahoo.com/markets/stocks/articles/novo-nordisk-cpse-novo-b-130956416.html

Prescribed peptides from $99/moSee all →